Biodexa Pharmaceuticals PLC - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of July 2026 for Biodexa Pharmaceuticals PLC, a foreign private issuer headquartered in Cardiff, United Kingdom. The filing serves to distribute a Notice of General Meeting and associated proxy forms to shareholders and American Depositary Share (ADS) holders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance notification and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses solely on the administrative distribution of meeting materials.
Guidance, Outlook, and Corporate Actions
The Company has scheduled a General Meeting for July 29, 2026, at 11:00 a.m. London time. The meeting will be held at the Company's registered office at 1 Caspian Point, Caspian Way, Cardiff, Wales, CF10 4DQ. Proxy forms for both ordinary shares and ADS holders have been distributed. The filing explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Key Facts for Investor Verification
- General Meeting Date: July 29, 2026.
- Meeting Time: 11:00 a.m. (London time).
- Meeting Location: 1 Caspian Point, Caspian Way, Cardiff, Wales, CF10 4DQ.
- Exhibits 99.1, 99.2, and 99.3 contain the Notice of General Meeting and proxy forms.
- No financial results or operational guidance are included in this specific filing.